Librium Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

Chlordiazepoxide HCl may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a vehicle or operating machinery.  Similarly, it may impair mental alertness in children.  The concomitant use of alcohol or other central nervous system depressants may have an additive effect.  PATIENTS SHOULD BE WARNED ACCORDINGLY.

Usage in Pregnancy:  An increased risk of congenital malformations associated with the use of minor tranquilizers (chlordiazepoxide, diazepam and meprobamate) during the first trimester of pregnancy has been suggested in several studies.  Because use of these drugs is rarely a matter of urgency, their use during this period should almost always be avoided.  The possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy should be considered.  Patients should be advised that if they become pregnant during therapy or intend to become pregnant they should communicate with their physicians about the desirability of discontinuing the drug.

Withdrawal symptoms of the barbiturate type have occurred after the discontinuation of benzodiazepines.  (See DRUG ABUSE AND DEPENDENCE section.)

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.


Librium is indicated for the management of anxiety disorders or for the short term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety.  Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.

The effectiveness of Librium in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies.  The physician should periodically reassess the usefulness of the drug for the individual patient.


There is currently no drug history available for this drug.

Other Information

Librium, the original chlordiazepoxide HCl and prototype for the benzodiazepine compounds, was synthesized and developed at Hoffmann-La Roche Inc.  It is a versatile therapeutic agent of proven value for the relief of anxiety.  Librium is among the safer of the effective psychopharmacologic compounds available, as demonstrated by extensive clinical evidence.

Librium is available as capsules containing 5 mg, 10 mg or 25 mg chlordiazepoxide HCl.  Each capsule also contains corn starch, lactose and talc.  Gelatin capsule shells may contain methyl and propyl parabens and potassium sorbate, with the following dye systems:  5-mg capsules – FD&C Yellow No. 6 plus D&C Yellow No. 10 and either FD&C Blue No. 1 or FD&C Green No. 3.  10-mg capsules – D&C Yellow No. 10 and either FD&C Blue No. 1 plus FD&C Red No. 3 or FD&C Green No. 3 plus FD&C Red No. 40.  25-mg capsules– D&C Yellow No. 10 and either FD&C Green No. 3 or FD&C Blue No. 1.

Chlordiazepoxide hydrochloride is 7-chloro-2- (methylamino) -5-phenyl-3H-1,4-benzodiazepine 4-oxide hydrochloride.  A white to practically white crystalline substance, it is soluble in water.  It is unstable in solution and the powder must be protected from light.  The molecular weight is 336.22.  The structural formula of chlordiazepoxide hydrochloride is as follows:

Chemical Structure

Librium Manufacturers

  • Valeant Pharmaceuticals North America Llc
    Librium (Chlordiazepoxide Hydrochloride) Capsule, Gelatin Coated [Valeant Pharmaceuticals North America Llc]

Login To Your Free Account